@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix chebi: . @prefix go: . @prefix Protein: . @prefix sfam: . @prefix geneProductOf: . @prefix hasAgent: . @prefix obo: . @prefix occursIn: . @prefix do: . @prefix species: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 hasAgent: sub:_2; a go:0016301 . sub:_2 geneProductOf: sfam:MAPK%20Erk1%2F2%20Family; a Protein: . sub:_3 occursIn: do:3908, obo:CLO_0001601, species:9606; rdf:object sub:_1; rdf:predicate belv:decreases; rdf:subject chebi:40877; a rdf:Statement . sub:assertion rdfs:label "a(CHEBI:erlotinib) -| kin(p(SFAM:\"MAPK Erk1/2 Family\"))" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_5; pav:version "20131211" . sub:_4 prov:value "Erlotinib decreased cellular levels of phosphorylated ERK1/2, phosphorylated AKT, Rad51 protein, and mRNA in erlotinib-sensitive H1650, A549, and H1869 cells, leading to cell death via apoptosis (also Erlotinib decreased Rad51 protein levels by enhancing Rad51 mRNA and protein instability, so will add protein as well as exp)"; prov:wasQuotedFrom pubmed:19671683 . sub:_5 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:19671683; prov:wasDerivedFrom beldoc:, sub:_4 . } sub:pubinfo { this: dct:created "2014-07-03T14:33:36.090+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }